Pulse Biosciences Inc Stock News

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Pulse Biosciences, Inc. (Pulse or the Company) (NASDAQ: PLSE) investors concerning the Companys possible violations of federal securities laws. On February 8, 2022, Pulse announced that the U.S. Food and Drug Administration (FDA) concluded there was insufficient clinical evidence to support the Companys 510(k) submission to expand the label for the CellFX System to treat sebaceous hype

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Pulse Biosciences, Inc. (“Pulse” or the “Company”) (NASDAQ: PLSE) on behalf of investors concerning the Company’s possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On February 8, 2022, Pulse announced that the U.S. Food and Drug Administration (“FDA”) concluded there was insufficient clinical evidence to support the Company’s 510(k)

Pulse Biosciences Inc (NASDAQ: PLSE ) shares are tumbling after announcing an update to its recent FDA 510(k) submission to add sebaceous hyperplasia to expand the CellFX System''s current labeling. The Company received an Additional Information (AI) letter, stating that the Company did not provide sufficient clinical evidence for the expanded use Full story available on Benzinga.com

Shares of Pulse Biosciences have plummeted after the FDA issued the company an Additional Information letter in regards to expanding the label of its CellFX System.

Haemonetics HAE +13%. Second Sight Medical Products EYES +8%. Pulse Biosciences (PLSE) -36%. Karyopharm Therapeutics KPTI -22%.

Pulse Biosciences Inc (PLSE) shares closed today at 1.0% above its 52 week low of $13.55, giving the company a market cap of $405M. The stock is currently down 7.6% year-to-date, down 46.3% over the past 12 months, and up 115.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.7%. Trading Activity Trading volume this week was 16.7% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 7.0% The company's stock price performance over the past 12 months lags the peer average by 359.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Pulse Biosciences Inc (PLSE) shares closed 0.4% lower than its previous 52 week low, giving the company a market cap of $438M. The stock is currently down 0.1% year-to-date, down 39.7% over the past 12 months, and up 135.9% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 0.1%. Trading Activity Trading volume this week was 13.2% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -94.4% The company's stock price performance over the past 12 months lags the peer average by 611.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

State Street Corp boosted its position in shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) by 6.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 243,619 shares of the companys stock after purchasing an additional 14,050 shares during the period. State Street Corps [] The post State Street Corp Raises Stock Position in Pulse Biosciences, Inc. (NASDAQ:PLSE) appeared first on ETF Daily News .

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Pulse Biosciences (NASDAQ:PLSE) announced its quarterly earnings data on Monday. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the Zacks consensus estimate of ($0.53) by $0.05, Fidelity Earnings reports. During the same quarter in the previous year, the firm earned ($0.51) earnings per share. PLSE stock traded down $0.18 during trading []

Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q3 2021 Results - Earnings Call Transcript

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation (NPS) technology, today announced financial results for the third quarter of 2021. Recent Highlights Achieved third quarter 2021 revenue of $574 thousand, representing 12 Controlled Launch Program participants opting to acquire their CellFX Systems and transition to commercial use Onboarded 68 CellFX System Controll

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences. Among the